Early induction intensification with cladribine, cytarabine, and mitoxantrone (CLAM) in AML patients treated with the DAC induction regimen: a prospective, non-randomized, phase II study of the Polish Adult Leukemia Group (PALG)Agnieszka Pluta, Agnieszka Wierzbowska, Sebastian Giebel et al.|Leukemia & lymphoma/Leukemia and lymphoma|2019Cited by 3
Analysis of Predictive Factors for Early Response to Ruxolitinib in 320 Patients with Myelofibrosis From the Polish Adult Leukemia Group (PALG) RegistryJoanna Góra-Tybor, Krzysztof Jamroziak, Aleksandra Gołoś et al.|Clinical Lymphoma Myeloma & Leukemia|2022Cited by 2
A compelling case for central pathology review of multiparameter flow cytometry measurable residual disease results in Acute Myeloid Leukemia (AML) clinical trials: Data from the PALG-AML1/2016 multicenter randomized studyAgnieszka Wierzbowska, Gail J. Roboz, Anna Czyż et al.|Blood|2025Cited by 1
Cladribine, Cytarabine and Mitoxantrone As Treatment Intensification for Patients with Acute Myeloid Leukemia with the Excess of Bone Marrow Blasts on Day 14 of the First Induction. Prospective, Multicenter Study By the Polish Adult Leukemia Group (PALG)Agnieszka Pluta, Agnieszka Wierzbowska, Kamil Brzozowski et al.|Blood|2016Cited by 1
Pre-Transplant Multiparameter Flow Cytometric Measurable Residual Disease in Acute Myeloid Leukemia As an Independent Prognostic Factor for Survival after Myeloablative Allogeneic Hematopoietic Cell TransplantationAnna Czyż, Agnieszka Wierzbowska, Małgorzata Sobczyk‐Kruszelnicka et al.|Blood|2022Cited by 0